“Becoming a member of ARMI|BioFabUSA was a natural extension for WEST,” said Scott Young, Vice President of Research. He added, “We have completed several programs with DEKA and have supported this new organization since its inception.”
West Pharmaceutical Services, Inc. (NYSE: WST) is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. WEST works with customers from concept to patient creating products that promote the efficiency, reliability and safety of the world's pharmaceutical drug supply.
“Packaging will be very important to regenerative medicine as it progresses and there are a lot of ‘ad hoc’ offerings out there now. We see the use of cells and tissue helping pharmaceutical clinical trials in the near-term and possibly five to seven years for human organs,” Young predicted.
As a global manufacturer in the design and production of technologically advanced, high quality, integrated containment and delivery systems for injectable medicines, WEST works with the world’s top pharmaceutical and biotechnology companies to improve patient health.
“We are excited to join ARMI and be at the forefront in the process of standardization for this new industry.” Young continued by stating, “The products needed for the future in regenerative medicine will require very specific clean, safe, and cost-efficient systems especially when mass produced for patients. They will need to validate the origin of the cells and ensure all safety concerns.”
Headquartered in Exton, Pennsylvania, the company and its 7,500 global employees support customers from locations in North and South America, Europe, Asia and Australia. Along with more than 95 years of experience, WEST brings customers quality, safety and reliability in injection molding, contract assembly and finished packaging from eight locations throughout North America and Europe.
“We recently opened a new facility in Waterford, Ireland as a global center of excellence for our advanced manufacturing network. In addition to a tighter particulate specification, our new Westar Select product line will be made available with multi-site production capabilities to ensure a continuous supply chain, while helping to reduce regulatory complexity for customers, which can assist companies in the new regenerative medicine industry,” he said.
The new, 20,500 square meter facility, situated on a 44-acre campus in Waterford, Ireland, will produce West's proprietary elastomeric laminate sheeting, which is used to package insulin for use in pen injectors. Additionally, it will offer high-value finishing for components, including stoppers and plungers, produced at other West facilities around the world. These services which are designed to mitigate the risk of potential contamination and compatibility issues with packaging components, include pharmaceutical washing, steam sterilization, and flexible packaging offerings.
The opening of West’s Waterford facility accompanied the launch of Westar Select components, the latest in West’s industry-leading Westar quality enhancement offering. Westar Select helps reduce variability and its effects on drug quality, safety and efficacy. The new Westar Select components offer even tighter particulate specification, a defined Global Product Portfolio focused on component capability, and a simplified regulatory strategy.
West boasts a single-source solution from product conceptualization through manufacturing and final packaging to ensure high-quality packaging and delivery. Westar Select components will be available through an optimized global manufacturing network with multi-site production capabilities to help ensure a continuous supply chain, while reducing regulatory complexity for customers.
Offering proprietary packaging, containment and drug delivery products, West's 2017 net sales of $1.6 billion reflect approximately 112 million of its components and devices, which are designed to improve the delivery of healthcare to patients worldwide. As a leader in innovative technology – including Daikyo Crystal Zenith® vial and syringe containment systems and devices such as the SmartDose drug delivery platforms, a pre-programmable and pre-loaded device – are designed around patient use to instill comfort and enable better health outcomes. West prides itself on inventive ways to advance integrated containment and delivery solutions and is dedicated to meeting the needs of their pharmaceutical partners.
"At West, we understand that our customers are increasingly challenged in the regenerative medicine industry to meet new and expanding regulatory requirements, and with that comes an expectation for the highest quality in drug delivery and packaging components, and we look forward to collaborating with the members on these issues," Young noted.